news
New insights about the development of hematopoietic stem cells
Understanding the involvement of Nod1 in the development of blood stem cells could greatly improve blood disorder treatments.
List view / Grid view
lymphoma
article
The future of lymphoma treatment
In the current landscape of drug discovery, lymphoma poses a significant challenge and opportunity. Researchers are fervently exploring novel therapeutic avenues, such as Antibody-Drug Conjugates (ADCs), to address the complexities of lymphoma. ARC-02, a standout candidate, demonstrates enhanced efficacy and tolerability in lymphoma treatment. While eyeing a diverse ADC pipeline,…
news
Cancer-killing T cells enhanced by engineered bacteria
Bacteria programmed to paint targets on solid tumours for T cells to see eliminates the need for specific antigens.
news
Novel method could determine which lymphoma patients will respond to CAR T-cell therapy
A new high-throughput approach has shown how patients whose tumours express CD58 are more likely to respond to CAR T-cell therapy.
article
How to develop the next generation of CAR T-cell therapies
CAR T cells have shown incredible promise in the clinic, but there is still room for advancement. One avenue for improvement is through modification of the CAR design. However, given the number of exchangeable domains, testing all variations can present a hurdle. In this article, Dr Sarwish Rafiq, Assistant Professor in…
news
Nanotechnology boosts immune response at tumour site in mice
The new nanotechnology left six of 10 mice with lymphoma tumour-free and was effective in melanoma when combined with existing drugs.
article
Determining the structure of nanobodies using nuclear magnetic resonance spectroscopy
Scientists at the New York University (NYU) Abu Dhabi have used nuclear magnetic resonance (NMR) techniques to determine the structure of a specific nanobody, Nb23. Drug Target Review’s Victoria Rees spoke with lead researcher Professor Gennaro Esposito to find out how their findings could lead to a better understanding of…
article
The other end of the antibody: Fc biology and immunotherapy
Dr Björn Frendeus outlines how the growing biology surrounding the inhibitory Fc receptor FcγRIIb defines a target for improving existing and future antibody treatments.
news
Natural killer cells and bispecific antibody target lymphoma tumours
In pre-clinical studies, researchers showed that cord blood-derived natural killer cells and a bispecific antibody eliminated lymphoma cells.
article
A novel CAR T-cell therapy to treat lymphomas
A new form of CAR T-cell therapy has shown promise in mice models to treat blood cancers; this article delves into the development behind the therapy.
article
CRISPR: three new developments in the world of gene editing
In this article, we outline three recent studies that have advanced the potential uses of CRISPR in the biomedical field.
news
New treatment approach kills lymphoma while sparing healthy cells in mice
By combining natural killer cells with a new molecule called Sialyl-Lewis X, researchers were able to treat lymphoma in mice.
news
Experimental CAR T therapy targets solid tumour cancer cells
Scientists have developed a novel chimeric antigen receptor (CAR) T-cell therapy to target a variety of human and murine solid-tumour cancer cells.
news
Using blue light to control CAR T cells and destroy tumours
Researchers have created a method to activate CAR T cells with blue LED light to successfully combat solid tumours in mice.
news
New class of drugs with potential to fight leukaemia and lymphoma discovered
PROTAC drugs that safely and effectively target leukaemia and lymphoma cells have been developed by researchers.